Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administered by aerosol

2024-515933-14-00 Protocol C20-48 Human pharmacology (Phase I) - First administration to humans Ended

Start 14 Apr 2025 · End 17 Apr 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol C20-48

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 60
Countries 1
Sites 1

Pneumonia

Key facts

Sponsor
Institut National De La Sante Et De La Recherche Medicale
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08], Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
14 Apr 2025 → 17 Apr 2026
Decision date (initial)
2024-10-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Pneumonia

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut National De La Sante Et De La Recherche Medicale

Sponsor organisation
Institut National De La Sante Et De La Recherche Medicale
Address
101 Rue De Tolbiac
City
Paris Cedex 13
Postcode
75654
Country
France

Scientific contact point

Organisation
Institut National De La Sante Et De La Recherche Medicale
Contact name
Antoine Guillon

Public contact point

Organisation
Institut National De La Sante Et De La Recherche Medicale
Contact name
Antoine Guillon

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 60 1
Rest of world 0

Investigational sites

France

1 site · Ended
Centre Hospitalier Regional Universitaire De Tours
Intensive Care Medicine Department, 2 Boulevard Tonnelle, 37044, Tours Cedex 9

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-04-14 2026-04-17 2025-04-14 2026-03-31

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-30 France Acceptable with conditions
2024-10-24
2024-10-24
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-14 France Acceptable with conditions 2025-03-20